Pharmaceuticals News and Research

RSS

Sapient Discovery, Helicon Therapeutics enter structural biology collaboration

Sapient Discovery, LLC., a structure-guided drug discovery company, announced today that it has entered into a research collaboration agreement with the Helicon Therapeutics, Inc., a San Diego based pharmaceutical company. Under the terms of the agreement, Sapient Discovery will apply its proprietary structural biology platform and expertise to determine the three-dimensional structures for targets of interest to Helicon Therapeutics, Inc.

16 Jun 2010

Immunomedics initiates dosing in milatuzumab-doxorubicin conjugate Phase I/II trial for relapsed multiple myeloma

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced the dosing of the first patient in a Phase I/II clinical trial of the doxorubicin conjugate of milatuzumab for the treatment of patients with relapsed multiple myeloma.

16 Jun 2010

ARBs may be linked with increased risk of developing cancer: US scientists

A common class of blood pressure drugs called angiotensin-receptor blockers may be linked with a slightly increased risk of developing cancer, US scientists have found.

16 Jun 2010

Hemispherx announces exclusive revenue sharing agreement with GP Pharm

Hemispherx Biopharma, Inc., announced that the Company executed an exclusive revenue sharing Sales, Marketing, Distribution and Supply Agreement for Argentina with GP Pharm Latinoamerica, an affiliate company of Spanish GP Pharm SA.

16 Jun 2010

LMBRI, Lipopharma Therapeutics collaborate to promote cancer drug development, improve patient outcomes

LMBRI LLC and Lipopharma Therapeutics SL today announced collaboration aimed at transforming cancer drug development and improving patient outcomes. Lipopharma developed new assessment approaches, methods and technologies for developing cancer therapeutics and diagnostics using their proprietary design of structure-based molecules that regulate the structure and functions of the membrane lipids, instead targeting cellular proteins, called "Membrane Lipid-Therapy".

16 Jun 2010

Bayer sues Teva, Barr in connection with oral contraceptive Gianvi

Today, Bayer HealthCare Pharmaceuticals Inc. and Bayer Schering Pharma AG sued Teva Pharmaceuticals USA, Inc., Barr Pharmaceuticals LLC, and Barr Laboratories, Inc. in the Northern District of Illinois (Chicago) for false advertising and patent infringement in connection with Teva's generic oral contraceptive, Gianvi™. Teva's product is sold as a generic version of Bayer HealthCare's leading oral contraceptive YAZ®.

16 Jun 2010

Galera Therapeutics completes Series 1 financing

Galera Therapeutics, a drug development company focused on novel therapeutics to protect against the side effects and increase the effectiveness of cancer treatment, today announced it has completed a Series 1 financing led by BioGenerator. Also participating in the round is Galera Angels, LLC, an angel investment group, and Analytical Bio-Chemistry Laboratories, Inc., of Columbia Missouri.

16 Jun 2010

Teva prices $2.5 billion debt offering

Teva Pharmaceutical Industries Limited announced today that it successfully priced the offering, by its special purpose finance subsidiaries, of a debt offering in three tranches:

16 Jun 2010

AmWINS Group Benefits re-launches EGWP program to help reverse negative effects of RDS

AmWINS Group Benefits launched the nation's first Employer Group Waiver Plan in 2006, and now in the wake of health care reform is re-launching their program as a direct and immediate approach to help reverse the negative effects of the Retiree Drug Subsidy, now taxable under the Patient Protection and Affordable Care Act.

15 Jun 2010

U.S. video, high-tech and integrated OR equipment market to exceed $2 billion by 2016

According to a new report by iData Research, the leading global authority in medical device and pharmaceutical market research, the overall U.S. video, high-tech and integrated operating room (OR) equipment market was worth $1.49 billion in 2009. This market, which experienced a strong decline during the economic recession, is expected to recover, exceeding $2 billion by 2016.

15 Jun 2010

Anacor's AN3365 novel systemic antibiotic achieves proof of concept

Anacor Pharmaceuticals today announced that a Joint Research Committee, composed of both GlaxoSmithKline (GSK) and Anacor employees, has determined that AN3365, a novel systemic antibiotic derived from Anacor's boron chemistry platform, has achieved proof of concept as defined under the collaboration agreement between GSK and Anacor.

15 Jun 2010

ATMI introduces new range of single-use bioprocess vessels

ATMI, Inc. today unveiled an important extension to its Integrity™ product line for the biopharmaceutical and biotechnology industries with the introduction of a new range of single-use bioprocess vessels (BPVs). The Integrity BPVs were launched at the IBC Single-Use Applications for Biopharmaceutical Manufacturing event, taking place now through Wednesday, June 16, 2010.

15 Jun 2010

CDI, Promega enter collaboration for toxicity testing in drug discovery process

Cellular Dynamics International (CDI) and Promega have entered into a research collaboration with the goal of bringing more relevant and highly predictive toxicity testing to the drug discovery process. Pharmaceutical discovery scientists will now be able to combine bioassays with human cardiomyocytes to improve prediction of unintentional, detrimental side effects that have previously remained undetected until late in the development process or after release of the drug to the general public.

15 Jun 2010

Positive clinical trial results for Anacor Pharmaceuticals' AN2728 announced

Anacor Pharmaceuticals today announced positive clinical trial results for its lead phosphodiesterase-4 inhibitor, AN2728, a novel topical anti-inflammatory compound derived from Anacor's boron chemistry platform. These results were obtained from a multi-center, Phase 2b, randomized, double-blind, dose-ranging, bilateral trial comparing AN2728 ointment, 0.5% and 2.0%, applied once or twice daily, to vehicle in 145 patients with mild-to-moderate plaque-type psoriasis.

15 Jun 2010

AMRI announces acquisition of Hyaluron

AMRI today announced the acquisition of Hyaluron Inc., expanding AMRI's contract manufacturing capabilities to include cGMP manufacturing and sterile filling of parenteral drugs to the biopharmaceutical industry. AMRI has acquired all facilities and equipment as well as a highly trained and experienced staff of professionals with expertise in sterile GMP manufacturing. Purchase price, including debt, was approximately $27 million.

15 Jun 2010

CBIS shares owned by Cannex Therapeutics to be cancelled and re-issued to K&D

Cannabis Science, Inc., a pioneering U.S. biotech company developing pharmaceutical cannabis products announces Federal Court order for CBIS shares owned by Cannex Therapeutics controlled by Steve Kubby to be cancelled and re-issued to K&D. Both K&D and Cannabis Science denounce the "slanderous, malicious attacks" on the Company by its fired CEO Steve Kubby.

15 Jun 2010

Alexion's Soliris may benefit patients with thrombotic microangiopathy from uncontrolled complement activation

Researchers reported today that Soliris® (eculizumab), a first-in-class terminal complement inhibitor developed by Alexion Pharmaceuticals, Inc., may provide clinical benefits to patients with thrombotic microangiopathy (TMA) resulting from uncontrolled complement activation. TMA, the formation of blood clots in capillaries and small arteries, can lead to life-threatening damage in multiple organs including kidney failure, thrombocytopenia (abnormally low platelet count) and anemia.

15 Jun 2010

Adeona's HartLab expands diagnostic testing services to include full array of microbiology testing

Adeona Pharmaceuticals, Inc. announced that its wholly-owned CLIA-certified clinical testing subsidiary, HartLab, has expanded its in-house diagnostic testing services to include a full array of microbiology testing. Adeona believes that that this expansion of services will be accretive to HartLab's revenues in the current quarter and beyond and is consistent with Adeona's plans to continue to build the revenues of its HartLab subsidiary.

15 Jun 2010

EMA COMP grants orphan medicinal product designation for Raptor's DR Cysteamine for cystinosis

Raptor Pharmaceutical Corp., announced that the European Medicines Agency's ("EMA") Committee for Orphan Medicinal Products ("COMP") has issued a positive opinion recommending orphan medicinal product designation for DR Cysteamine for the potential treatment of cystinosis.

15 Jun 2010

Orasi Medical signs agreement to study effect of Lundbeck CNS compounds on human brain

Orasi Medical today announced that it has entered an agreement with H. Lundbeck A/S to study the effect of Lundbeck central nervous system compounds on the human brain.

15 Jun 2010

Pharmaceuticals News and Research

Sapient Discovery, Helicon Therapeutics enter structural biology collaboration

Immunomedics initiates dosing in milatuzumab-doxorubicin conjugate Phase I/II trial for relapsed multiple myeloma

ARBs may be linked with increased risk of developing cancer: US scientists

Hemispherx announces exclusive revenue sharing agreement with GP Pharm

LMBRI, Lipopharma Therapeutics collaborate to promote cancer drug development, improve patient outcomes

Bayer sues Teva, Barr in connection with oral contraceptive Gianvi

Galera Therapeutics completes Series 1 financing

Teva prices $2.5 billion debt offering

AmWINS Group Benefits re-launches EGWP program to help reverse negative effects of RDS

U.S. video, high-tech and integrated OR equipment market to exceed $2 billion by 2016

Anacor's AN3365 novel systemic antibiotic achieves proof of concept

ATMI introduces new range of single-use bioprocess vessels

CDI, Promega enter collaboration for toxicity testing in drug discovery process

Positive clinical trial results for Anacor Pharmaceuticals' AN2728 announced

AMRI announces acquisition of Hyaluron

CBIS shares owned by Cannex Therapeutics to be cancelled and re-issued to K&D

Alexion's Soliris may benefit patients with thrombotic microangiopathy from uncontrolled complement activation

Adeona's HartLab expands diagnostic testing services to include full array of microbiology testing

EMA COMP grants orphan medicinal product designation for Raptor's DR Cysteamine for cystinosis

Orasi Medical signs agreement to study effect of Lundbeck CNS compounds on human brain

Ultimate guide to the essential tools for the characterization of proteins, polymers and nanoparticles eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence